Ildong, Cellivery To Co-Develop Novel Biologic For Parkinson's
This article was originally published in PharmAsia News
South Korean pharma firm Ildong and bioventure Cellivery have tied up to jointly develop an early stage, first-in-class therapy for Parkinson's disease using Cellivery's platform technology. The two hope the partnership will fundamentally change the therapeutic approach to the neurodegenerative disease.
You may also be interested in...
Marking the first Korean company to launch an initial public offering on the recommendation of its lead broker, Cellivery Therapeutics is slated to use the upcoming proceeds to progress preclinical trials of its lead assets for Parkinson's disease and pancreatic cancer, which the company aims to license out to global partners in the early development stages.
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.